Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN-DBS for Pharmacoresistant Partial Epilepsy
NCT02076698Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2014
- Primary completion
- Nov 2021
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in partial epilepsy, sponsored by CHU Grenoble Alpes. Primary endpoint: Assessment of effectiveness of thalamic DBS on seizures severity at 2 years. Started Jun 2014; status: completed.
02
Conditions
partial epilepsy
Beyond the preview
Go deeper on NCT02076698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076698.